Site content is prepared and reviewed under the supervision of Prof. Dr. Burak Tatlı (Paediatric Neurologist).
Health article

Duchenne guide: From CK to prognosis, from steroids to gene therapy

7 October 2026·Prof. Dr. Burak Tatlı
Duchenne guide: From CK to prognosis, from steroids to gene therapy

Overview

Duchenne Muscular Dystrophy (DMD) is the most common inherited muscle disease of childhood (~1/3,500-5,000 male births). Dystrophin, which protects muscle against mechanical stress, cannot be produced; the muscle fibre is damaged with every contraction. With standardised multidisciplinary care and new treatments, the natural course has changed considerably.

Genetic Cause

The X-linked DMD gene (the largest in the genome): deletions (~65%), duplications (~10%) and point mutations. If the reading frame is preserved, the milder Becker phenotype is seen. About 1/3 of cases are de novo; in the rest the mother is a carrier → maternal testing is essential, and cardiac follow-up (intermittent echo/MRI in adulthood) is recommended for carrier women.

Clinical Course

Diagnosis

Treatment and Follow-up

Steroids — the main treatment

Heart and respiration

Surgery-anaesthesia warning

Succinylcholine is contraindicated in DMD; inhaled anaesthetics carry a risk of a rhabdomyolysis-like reaction — the team must be informed before every procedure (a written card).

Physiotherapy-orthopaedics

Prognosis — An Honest Framework

Treatment Pipeline — The Position in October 2026

This field changes quickly, and the direction of change is not always forward: over the past two years the scope of some medicines has been narrowed and some confirmatory trials did not meet their targets. The picture below is valid as of 31 October 2026. A medicine being approved in another country does not mean there is marketing authorisation, actual supply or reimbursement in Türkiye; each of these has to be verified separately.

Exon skipping medicines

Ataluren — European authorisation not renewed

The conditional European authorisation for ataluren, developed for nonsense (premature stop codon) variants, was not renewed on 28 March 2025 on the grounds that clinical efficacy could not be confirmed. Presenting the former European indication as a current, active authorisation is incorrect. This process shows that conditional approval carries an ongoing obligation to generate evidence.

Microdystrophin gene therapy (delandistrogene moxeparvovec / Elevidys)

Approaches at the research stage

How to read this: an increase in dystrophin on biopsy shows that the biological target has been reached; on its own it does not determine the size of any meaningful benefit for the child in walking, arm use, heart or breathing. A medicine producing a higher dystrophin percentage does not prove its clinical superiority over another. In a progressive disease staying stable can also be a valuable outcome; but without a comparison group it cannot be established that the stabilisation was caused by the treatment.

Current picture: Genetic Treatments — Duchenne treatment pipeline.

Follow-up: What Became Clearer in 2025-2026

Alongside the treatment headings, points have also become clearer in follow-up itself over the past two years. These are talked about less than new medicines, but this is the part that affects daily life the most.

A resource for Türkiye

The Ministry of Health's Duchenne Muscular Dystrophy Clinical Guideline was published in September 2025. This 174-page national resource is the reference document for how care is to be organised within the country. Since an approval decision abroad does not mean marketing authorisation, actual supply or reimbursement in Türkiye, the current status at the Turkish Medicines and Medical Devices Agency (TİTCK) and the Social Security Institution (SGK) has to be verified separately for each medicine.

Questions you can ask at your appointment

Daily Life


Downloadable: Duchenne Emergency Action Plan (PDF)

You can download the 3-page emergency action plan prepared for children with Duchenne by Nörogender, under the guidance of Prof. Dr. Burak Tatlı. At the centre of the form are DMD's four emergency pillars: steroid stress dosing (chronic cortisone must never be stopped abruptly; continue intravenously in a vomiting child), the heart (ECG + troponin for chest pain/palpitations; a note that "CK is already high"), anaesthesia (succinylcholine strictly forbidden, avoidance of gas anaesthetics), and a warning about fat embolism after fracture. The identification section has spaces reserved for steroid and cardiac medicines. The third page is a medical information note with dosing boxes, for healthcare professionals.

There is also a Routine Follow-up Calendar (2 pages): a year-by-year table and record chart built around four pillars — steroid adverse effect monitoring, annual cardiac assessment (echo/cardiac MRI + ECG), respiration (FVC-cough-night-time), and bone-scoliosis.

📄 Emergency Action Plan (PDF, 3 pages) — in Turkish   📅 Routine Follow-up Calendar (PDF, 2 pages) — in Turkish

Complete the form together with your doctor; keep one copy at home and one at school, and show it to the team before every surgery/anaesthesia.

The content of this site is for information only; please consult your own physician for diagnosis and treatment decisions.